Spondyloarthritis

June 15, 2021

Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).

June 09, 2021

Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."

April 22, 2021

Investigators discovered that women with axial spondyloarthritis (axSpA) have an overall higher disease burden and more peripheral manifestations when compared with men. They further theorized that awareness of these differences and the way the condition presents differently in both sexes may be used to more easily identify axSpA and improve disease management.

October 15, 2020

Back pain is the second leading symptom prompting a visit to a primary care physician. Here, we highlight a review of axial spondyloarthritis from Mayo Clinic Proceedings. The review aims to help primary care physicians detect this condition and know when to refer to a rheumatologist.

July 30, 2020

Patients with axial spondyloarthritis who smoke may be more likely to have sacroiliac joint inflammation if they have a blue‐collar job or low education, according to a study recently published in Arthritis & Rheumatology. In this Q&A with study author Elena Nikiphorou, M.B.B.S./B.Sc., M.D.(Res), Consultant Rheumatologist at King's College Hospital in London, U.K.,we discuss the study and its findings.

July 30, 2020

Patients with axial spondyloarthritis may be more susceptible to higher disease activity if they are overweight or obese, according to a systematic review and meta-analysis published in RMD Open. In this Q&A with study author Jean Liew, M.D., of University of Washington in Seattle, we discuss the study and its significance.

June 23, 2020

French researchers writing in Arthritis and Rheumatology report that of 609 surveyed spondyloarthritis patients self-isolating at home due to COVID-19, most say their condition has progressed while in isolation and for some, the change has been considerable.

June 08, 2020

The increased cardiovascular disease risk in patients with ankylosing spondylitis is explained both by traditional  cardiovascular risk factors as well as the underlying chronic inflammatory process. However, this dual etiology is not adequately addressed in clinical practice, according to a presentation on June 3 at the European Congress of Rheumatology (EULAR) annual meeting.

June 08, 2020

Spondyloarthritis is associated with an increased risk of preterm births, small gestational age infants and elective cesarean section deliveries, according to study data presented on June 4 at the European Congress of Rheumatology (EULAR) annual meeting.

June 04, 2020

Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.